Clearmind Medicine Appoints New Board Member
Ticker: CMND · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1892500
Sentiment: neutral
Topics: board-appointment, management-change, pharmaceuticals
Related Tickers: RVSN
TL;DR
Clearmind Medicine adds Hila Kiron-Revach to its board.
AI Summary
Clearmind Medicine Inc. announced on September 26, 2024, the appointment of Hila Kiron-Revach to its Board of Directors. Ms. Kiron-Revach brings experience from her current board positions at Rail Vision Ltd. and Geffen Biomed Ltd.
Why It Matters
The addition of a new director can signal strategic shifts or bring new expertise to the company's leadership.
Risk Assessment
Risk Level: low — This filing is a routine corporate announcement regarding a board appointment and does not involve financial transactions or significant operational changes.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer
- Hila Kiron-Revach (person) — Newly appointed Board Member
- Rail Vision Ltd. (company) — Company where Hila Kiron-Revach is a board member
- Geffen Biomed Ltd. (company) — Company where Hila Kiron-Revach is a board member
FAQ
When was Hila Kiron-Revach appointed to the Clearmind Medicine Inc. Board of Directors?
Hila Kiron-Revach was appointed to the Board of Directors, effective September 26, 2024.
What other public company board does Hila Kiron-Revach currently serve on?
Hila Kiron-Revach has served on the board of directors of Rail Vision Ltd. (Nasdaq: RVSN) since January 2024.
What is the filing type for this report?
This is a Form 6-K report, which is a Report of Foreign Private Issuer.
What is the fiscal year end for Clearmind Medicine Inc.?
The fiscal year end for Clearmind Medicine Inc. is October 31.
What is the primary business of Clearmind Medicine Inc. according to the filing?
Clearmind Medicine Inc. is classified under Pharmaceutical Preparations [2834].
Filing Stats: 413 words · 2 min read · ~1 pages · Grade level 9.4 · Accepted 2024-09-26 16:01:17
Filing Documents
- ea021579801-6k_clearmind.htm (6-K) — 11KB
- 0001213900-24-082230.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: September 26, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer